

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
15/WA/0189	Bedside Inotropy ? validation of a non-invasive technique to rapidly measure cardiac contractility	18/05/2015	08/06/2015	21	Yes												
10/H0802/46	Revascularisation for Ischaemic Ventricular Dysfunction (REVIVED)	12/06/2015													Y	This study has a difficult patient population with unfortunately 40-50% of patients dying before they can be approached. There have also been some staffing capacity issues around MRI reporting.	Neither
13/SC/0645	Pre-eclampsia in Hospital: Early Induction or Expectant Management	18/03/2015	01/07/2015	105	No					Y						Staff sickness and annual leave. First patient recruited 01/07/2015.	NHS Provider
14/SC/1223	A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.	22/06/2015							Y						Y	Delay in Site Initiation Visit by sponsor and issues with NHS Provider Pharmacy. Site activated by sponsor on 21/10/2015.	Both
14/SC/0033	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	07/07/2015							Y	Y						Site not activated by sponsor until 01/10/2015. PI then on annual leave.	Both
14/SC/0032	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	07/07/2015							Y	Y						Site not activated by sponsor until 01/10/2015. PI then on annual leave.	Both
14/YH/0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	09/07/2015	19/08/2015	41	Yes												

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
11/SS/0100	A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine for six months in patients with a recent stroke	29/07/2015	14/09/2015	47	Yes												
15/SC/0085	A feasibility study with a crossover design to assess the diagnostic accuracy of acetic acid targeted biopsies versus non targeted biopsies (current practice) for detection of dysplasia during Barrett's surveillance: the ABBA study.	17/09/2015								Y						Very recently approved study. Staff availability issues over the summer holiday period.	NHS Provider
15/LO/0802	The effect of standard versus high energy, low volume oral nutritional supplements in children requiring nutritional support – a pilot trial	28/07/2015								Y						Staff availability issues over the summer holiday period. First patient recruited 19/10/15.	NHS Provider
15/WS/0061	A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure	09/09/2015							Y							Very recently approved study. Study was initiated on 08/10/2015 but study medication was not received until recently. Currently screening for suitable patients.	Sponsor